LSB - רווח לפני ניכוי ריבית, מסים, בלאי ופחת ysbiopharm.com
The EBITDA trend shown on this GURU.Markets chart is based on the implementation of closed robotic lines to ensure product sterility. Growth is supported by the development of unique adjuvants and the creation of new vaccines. The current commercialization stage of rabies and COVID vaccines strengthens the base. The value of captures the current state of the absolute operating profit parameter for LakeShore Biopharma Co. (LSB).
LakeShore Biopharma (LSB) - פילוחי מדדים ודוחות פיננסיים
Absolute operating profit reflects the actual cash flow from core operations before depreciation and taxes, allowing for an assessment of business efficiency without accounting adjustments. By analyzing the consolidated EBITDA, an investor can identify hidden financial pressure on LakeShore Biopharma (LSB), driven by high vaccine development costs and regulatory risks within the Chinese market.
